Introgen Therapeutics, Inc. Announces the Transfer of its Listing of Common Stock from the Nasdaq Global Market to the Nasdaq Capital Market
Published: Nov 19, 2008
AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN), today announced that it has received notice from the Nasdaq Hearings Panel (the “Panel”) that the listing of the company's common stock will be transferred from The Nasdaq Global Market to The Nasdaq Capital Market effective with the opening of trading on November 19, 2008. The company’s shares will continue to be listed on that market provided that Introgen can demonstrate compliance with all listing requirements of the Nasdaq Capital Market by March 3, 2009. The company's shares will continue to trade under the ticker "INGN."